Michael Kolodziej, MD, explains, the benefit of using biomarkers from a payer perspective to ensure that the right patient gets the right treatment.
Michael Kolodziej, MD, explains, the benefit of using biomarkers from a payer perspective to ensure that the right patient gets the right treatment.
“Many of the new therapies, whether they be targeted agents or immunotherapies are extremely expensive,” he said. “We can get into long debate about what the right or fair price is, but I think because of the high cost, there is a lot of scrutiny in the managed care world to make sure that the right patient gets the treatment.”
He added that it can be difficult to know where treatments belong in the sequence of therapy. While some people are of the opinion that these treatments should be used earlier rather than later, payers prefer to manage to what the FDA decides.
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen